Payment overview · 2025
General Payments
$69.22
3 reported records · 2 companies
Healthcare provider profile · identity verified
Patrick J. Fox, MD
Allopathic & Osteopathic Physicians|Family Medicine · MENA, AR · NPI 1003963208
Verified facts
What the public records show
CMS Open Payments records show Patrick J. Fox, MD received $69.22 in general payments during 2025 across 3 reported records.
ABBVIE INC. accounted for 74.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.55 | 74.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.67 | 25.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $69.22 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
125 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 475 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 101 |
| Omeprazole | Omeprazole | 383 | 85 |
| Gabapentin | Gabapentin | 379 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 339 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 266 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 63 |
| Tramadol Hcl | Tramadol Hcl | 225 | 47 |
| Lisinopril | Lisinopril | 205 | 57 |
| Prednisone | Prednisone | 201 | 109 |
| Potassium Chloride | Potassium Chloride | 196 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 184 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 45 |
| Losartan Potassium | Losartan Potassium | 181 | 53 |
| Trazodone Hcl | Trazodone Hcl | 177 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 43 |
| Simvastatin | Simvastatin | 166 | 40 |
| Montelukast Sodium | Montelukast Sodium | 165 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 164 | 76 |
| Furosemide | Furosemide | 155 | 45 |
| Sertraline Hcl | Sertraline Hcl | 153 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 147 | 28 |
| Baclofen | Baclofen | 144 | 44 |
| Eliquis | Apixaban | 143 | 27 |
| Meloxicam | Meloxicam | 142 | 38 |
| Glipizide | Glipizide | 136 | 28 |
| Dexamethasone | Dexamethasone | 128 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 31 |
| Finasteride | Finasteride | 125 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 125 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 124 | 87 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 114 | 32 |
| Spironolactone | Spironolactone | 111 | 22 |
| Carvedilol | Carvedilol | 106 | 23 |
| Celecoxib | Celecoxib | 106 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 22 |
| Metformin Hcl | Metformin Hcl | 91 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 19 |
| Famotidine | Famotidine | 89 | 16 |
| Alprazolam | Alprazolam | 87 | 17 |
| Allopurinol | Allopurinol | 86 | 19 |
| Alendronate Sodium | Alendronate Sodium | 82 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 29 |
| Buspirone Hcl | Buspirone Hcl | 72 | 15 |
| Pregabalin | Pregabalin | 71 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 70 | 16 |
| Mirtazapine | Mirtazapine | 69 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 20 |
| Ozempic | Semaglutide | 66 | 15 |
| Memantine Hcl | Memantine Hcl | 63 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 53 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 13 |
| Warfarin Sodium | Warfarin Sodium | 61 | suppressed |
| Jardiance | Empagliflozin | 57 | suppressed |
| Primidone | Primidone | 57 | suppressed |
| Estradiol | Estradiol | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 12 |
| Metolazone | Metolazone | 54 | 16 |
| Farxiga | Dapagliflozin Propanediol | 53 | suppressed |
| Ezetimibe | Ezetimibe | 52 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | 11 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Ondansetron Odt | Ondansetron | 47 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 13 |
| Topiramate | Topiramate | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Cephalexin | Cephalexin | 42 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 16 |
| Azithromycin | Azithromycin | 41 | 32 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | 13 |
| Desloratadine | Desloratadine | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 23 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 26 |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Levemir Flexpen | Insulin Detemir | 36 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 35 | 16 |
| Bumetanide | Bumetanide | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 14 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 16 |
| Lorazepam Intensol | Lorazepam | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bystolic | Nebivolol Hcl | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nystatin | Nystatin | 13 | 12 |
| Sucralfate | Sucralfate | 13 | 12 |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Butrans | Buprenorphine | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $69.22 · 3 records | ABBVIE INC. | QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error